Lataa...
Steroid sidestep: Evading androgen ablation by abiraterone
Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well-defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in subset of patients progressing while receiving abiraterone, suggesting this may be a therapeutically exploitable mechanism of abir...
Tallennettuna:
| Julkaisussa: | Clin Cancer Res |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4359949/ https://ncbi.nlm.nih.gov/pubmed/25432158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2899 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|